P64.04 Hypo-Fractionated Versus Conventionally Fractionated Radiotherapy for Patients with LS-SCLC: An Open-Label, Randomized, Phase 3 Trial

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30070-5 ◽

2016 ◽

Vol 17 (8) ◽

pp. 1061-1069 ◽

Cited By ~ 201

Author(s):

Luca Incrocci ◽

Ruud C Wortel ◽

Wendimagegn Ghidey Alemayehu ◽

Shafak Aluwini ◽

Erik Schimmel ◽

...

Keyword(s):

Prostate Cancer ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30581-7 ◽

2021 ◽

Vol 22 (2) ◽

pp. 235-245

Author(s):

Per Fransson ◽

Per Nilsson ◽

Adalsteinn Gunnlaugsson ◽

Lars Beckman ◽

Björn Tavelin ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Life Outcomes ◽

Phase 3 ◽

Quality Of Life Outcomes ◽

Patient Reported ◽

Randomised Controlled ◽

MP47-02 SEXUAL FUNCTION AFTER HYPOFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY FOR PROSTATE CANCER: RESULTS OF THE PROSPECTIVE, RANDOMIZED PHASE 3 HYPRO TRIAL

The Journal of Urology ◽

10.1016/j.juro.2016.02.321 ◽

2016 ◽

Vol 195 (4S) ◽

Author(s):

Ruud Wortel ◽

Luca Incrocci

Keyword(s):

Prostate Cancer ◽

Sexual Function ◽

Phase 3 ◽

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00567-7 ◽

2016 ◽

Vol 17 (4) ◽

pp. 464-474 ◽

Cited By ~ 124

Author(s):

Shafak Aluwini ◽

Floris Pos ◽

Erik Schimmel ◽

Stijn Krol ◽

Peter Paul van der Toorn ◽

...

Keyword(s):

Prostate Cancer ◽

Late Toxicity ◽

Phase 3 ◽

Faculty Opinions recommendation of Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736033083.793568426 ◽

2020 ◽

Author(s):

James Eastham

Keyword(s):

Prostate Cancer ◽

Phase 3 ◽

Re: Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial

The Journal of Urology ◽

10.1097/01.ju.0000611500.33954.d2 ◽

2020 ◽

Vol 203 (1) ◽

pp. 32-32

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

Phase 3 ◽

Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.09.007 ◽

2020 ◽

Vol 106 (1) ◽

pp. 108-115 ◽

Cited By ~ 7

Author(s):

Kim C. de Vries ◽

Ruud C. Wortel ◽

Esther Oomen-de Hoop ◽

Wilma D. Heemsbergen ◽

Floris J. Pos ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Localized Prostate Cancer ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Fractionated Radiation Therapy ◽

Fractionated Radiation ◽

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30569-8 ◽

2019 ◽

Vol 20 (11) ◽

pp. 1531-1543 ◽

Cited By ~ 71

Author(s):

Douglas H Brand ◽

Alison C Tree ◽

Peter Ostler ◽

Hans van der Voet ◽

Andrew Loblaw ◽

...

Keyword(s):

Prostate Cancer ◽

Acute Toxicity ◽

Stereotactic Body Radiotherapy ◽

Open Label ◽

Phase 3 ◽

Intensity Modulated ◽

Open Label Phase

Re: Hypofractionated Radiotherapy versus Conventionally Fractionated Radiotherapy for Patients with Intermediate-Risk Localised Prostate Cancer: 2-Year Patient-Reported Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP Trial

The Journal of Urology ◽

10.1016/j.juro.2016.08.067 ◽

2016 ◽

Vol 196 (5) ◽

pp. 1445-1447

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

Patient Reported Outcomes ◽

Hypofractionated Radiotherapy ◽

Intermediate Risk ◽

Phase 3 ◽

Patient Reported ◽

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(19)31131-6 ◽

2019 ◽

Vol 394 (10196) ◽

pp. 385-395 ◽

Cited By ~ 139

Author(s):

Anders Widmark ◽

Adalsteinn Gunnlaugsson ◽

Lars Beckman ◽

Camilla Thellenberg-Karlsson ◽

Morten Hoyer ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 3 ◽